Use of nanotechnology-designed footsock in the management of preulcerative conditions in the diabetic foot: results of a single, blind randomized study.
The Difoprev system constituted by a sock loaded with nanocapsules containing a hydrating agent in the diabetic foot is tested. A total of 30 neuropathic outpatients with foot anhydrosis were randomized into group A, treated with the application of the sock with the nanocapsules, and group B wearing only the socks without the nanocapsules. Patients were blindly evaluated with a clinical score, hygrometry, transepidermal water loss, skin temperature, and skin hardness at baseline and after 6 weeks. No difference between the groups emerged at baseline. Although group B showed no changes at the end of the treatment, group A significantly (P< .05) improved in all the parameters evaluated. No adverse events were recorded in both groups during the study. The use of hydrating agents carried by nanocapsules-loaded socks is safe and effective for the neuropathic diabetic foot.
Banchellini
Elisa
E
Department of Endocrinology and Metabolism, Diabetic Foot Section, University of Pisa, Italy.
Macchiarini
Silvia
S
Dini
Valentina
V
Rizzo
Loredana
L
Tedeschi
Anna
A
Scatena
Alessia
A
Goretti
Chiara
C
Campi
Fabrizio
F
Romanelli
Marco
M
Piaggesi
Alberto
A
D001458:Bandages; D017719:Diabetic Foot / Q000628:therapy*; D004643:Emollients / Q000008:administration & dosage*; D006801:Humans; D007007:Hypohidrosis / Q000628:therapy*; D008081:Liposomes / Q000627:therapeutic use*; D016555:Matched-Pair Analysis; D008875:Middle Aged; D053769:Nanocapsules / Q000627:therapeutic use*; D016037:Single-Blind Method
D004643:Emollients; D008081:Liposomes; D053769:Nanocapsules